21 results on '"Cravioto, M C"'
Search Results
2. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus.
- Author
-
Mayorga, J., Alpízar-Rodríguez, D., Prieto-Padilla, J., Romero-Díaz, J., and Cravioto, M. C.
- Subjects
PREMATURE ovarian failure ,SYSTEMIC lupus erythematosus ,DISEASE prevalence ,HYSTERECTOMY ,AUTOIMMUNITY ,AMENORRHEA ,PATIENTS - Abstract
Objective To estimate the prevalence of premature ovarian failure (POF) and its associated factors in patients with systemic lupus erythematosus (SLE). Methods Cross-sectional study including consecutive SLE women <60 years of age attending a rheumatology clinic. A face-to-face interview was undertaken to obtain demographic, gynaecological and lupus characteristics. Additional rheumatologic and endocrine data were retrieved from patients’ medical records. POF prevalence was estimated in the study sample and in a subgroup of patients aged <40 years at interview. Associations between POF and selected variables were assessed by logistic regression analyses. Results A total of 961 patients were analysed. Prevalence of POF, secondary amenorrhea of known cause, menopause and hysterectomy were 5.4%, 0.8%, 7.8% and 4.4%, respectively. In 674 (70%) patients who had not been exposed to cyclophosphamide (CYC) the prevalence of POF was 0.6%. Disease activity over time (OR 1.4 (CI 95% 1.0–1.8, p < 0.05)) and CYC treatment (OR 5.9 (CI 95% 1.8–18.8, p < 0.01)) were associated with higher prevalence. Association between POF and endocrine autoimmune diseases was not found. Conclusions In the absence of CYC treatment, the prevalence of POF in lupus patients is consistent with that reported in the general population. The existence of autoimmune processes at the ovary seems unlikely in most lupus patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Steroid Hormone Contraception and Bone Mineral Density
- Author
-
PETITTI, D. B., primary, PIAGGIO, G., additional, MEHTA, S., additional, CRAVIOTO, M. C., additional, and MEIRIK, O., additional
- Published
- 2000
- Full Text
- View/download PDF
4. P-66. Pharmacokinetic and Pharmacodynamic Assessment of the 25-mg Estradiol Releasing Subcutaneous Implant in Postmenopausal Women
- Author
-
Cravioto, M. C., primary, Delgado-Baldiz??n, N., additional, Rico-Escobar, A., additional, D??az-S??nchez, V., additional, and Larrea, F., additional
- Published
- 1998
- Full Text
- View/download PDF
5. P-67. Menopause in Systemic Lupus Erythematosus (SLE). Age at Presentation and Clinical Characteristics
- Author
-
Cravioto, M. C., primary, Romero-D??az, J., additional, Mendoza-Fuentes, A., additional, Mestanza-Peralta, M., additional, and S??nchez-Guerrero, J., additional
- Published
- 1998
- Full Text
- View/download PDF
6. Latin American experience with two low-dose oral contraceptives containing 30 mg ethinylestradiol/75 mg gestodene and 20 mg ethinylestradiol/150 mg desogestrel
- Author
-
Bassol, S., Alvarado, A., Celis, C., Cravioto, M. C., Peralta, O., Montano, R., Novelli, J., Albornoz, H., Kesseru, E., and Soares, A.
- Published
- 2000
- Full Text
- View/download PDF
7. Mesigyna once-a-month combined injectable contraceptive: Experience in Latin America
- Author
-
Bassol, S., Cravioto, M. C., Durand, M., Bailon, R., Carranza, S., Fugarolas, J., Gaona, R., Parada, L. M., Celis, C., and Santoyo, S.
- Published
- 2000
- Full Text
- View/download PDF
8. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: I. Contraceptive efficacy and side effects
- Author
-
Said, S., Sadek, W., Knoieif, A., Koetsawang, Suporn, Kiriwat, Orawan, Piboonmanee, Surat, Rivera, R., Alvarado, G., Juarez, M.A., Aguliar, S., Santiso, R., Contreras, C.F., Galichi, L.F., Guliora, M., Alzugaray, M.G., Hernandez, M.L., Gallardo, J.R., Affandi, B., Santoso, S.S.I., Jamil, R.S., Kazi, A., Kononova, E.S., Ailpov, V.I., Apeio, R., Hernardo, E.S., Benitez, I., Canto-de-Cetina, T., Cardenas, S., Polanco, L., Vera, L., Cravioto, M.-C., Hernandez, L., Fuziwara, J.L., Garza-Flores, J., Perez-Palacios, G., Oropeza, G., Mota, E., Zavaleta, E., Benagiano, G., Bastianelli, C., Diaz Infante-Ibarra, A., Castelo, C.J., Jimenez, R., Perez-Arocha, N., Lang-Prieto, J., Casas-Fernandez, J.A., Perez-Paz, H.M., Perez, M., Hernandez, A.R., Bustillo Tur, C., Kovacs, L., Koroszar, S., Bassol, S., Trujilio, A.M., Guzman-Serani, R., Israel, E., Hall, P.E., d’Arcangues, C., Busca, B., Macnin, D., Pinol, A., Schlagenhaft, F., and Hall, Peter E.
- Abstract
Two once-a-month injectable contraceptive formulations, HRP112 (depot-medroxyprogesterone acetate, 25mg and estradiol cypionate, 5mg.) and HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg,) were compared in two groups of women witn regard to effectiveness, reported complaints and reasons for discontinuation. A total of 2328 women were recruited into a seventeen-centre, randomized clinical trial. Follow-up was for a period of one year and resulted in a total of 10,969 women-months of experience of HRP112 and 10,608 women-months of experience with HRP102.
- Published
- 1988
- Full Text
- View/download PDF
9. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. II. The comparison of bleeding patterns
- Author
-
World Health Organization, Null, Task Force On Long Acting Systemic Agents for Fertility Regulation, Null, Said, S., Sadek, W., Kholeif, A., Koetsawang, Suporn, Kiriwat, Orawan, Piboonmanee, Surat, Rivera, R., Alvarado, G., Juarez, M. A., Aquilar, S., Santiso, R., Contreras, C. F., Galichl, L. F., Guirola, M., Alzugaray, M. G., Hernandez, M. L., Gallarco, J. R., Affandi, B., Santoso, S. S. I., Samil, R. S., Kazi, A., Kononova, E. S., Alipov, V. I., Apelo, R., Bernardo, E. S., Benitez, I., Canto de Cetina, T., Cardenas, S., Polanco, L., Vera, L., Cravioto, M. C., Hernandez, L., Fuziwara, J. L., Garza Flores, J., Perez Palacios, G., Oropeza, G., Mota, E., Zavaleta, E., Benagiano, Giuseppe, Bastianelli, Carlo, Diaz Infante Ibarra, A., Castelo, C. J., Jiminez, R., Perez Arocha, N., Lang Prieto, J., Casas Fernandez, J. A., Perez Paz, H. M., Perez, M., Hernandez, A. R., Tur, C. Bustillo, Kovacs, L., Koloszar, S., Bassol, S., Trujillo, A. M., Guzman Serani, R., Israel, E., D'Arcangues, C., Busca, B., Hall, P. E., Machin, D., Pinol, A., and Schlagenhaft, F.
- Subjects
medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Medicine (all) ,Estradiol valerate ,Obstetrics and Gynecology ,Estradiol cypionate ,Discontinuation ,Surgery ,Clinical trial ,Reproductive Medicine ,medicine ,Vaginal bleeding ,Amenorrhea ,medicine.symptom ,Intramuscular injection ,business ,medicine.drug - Abstract
A multicentred Phase III clinical trial was conducted in 12 countries to compare HRP112 (depot-medroxyprogesterone acetate, 25 mg and estradiol cypionate, 5 mg) and HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg) given every 28 days. Contraceptive efficacy and side-effects of both regimens were reported previously. Their effect on vaginal bleeding patterns is the object of this paper. A total of 2320 women were randomly assigned to each drug and 2000 of them provided a menstrual diary. The comparison of the bleeding patterns is made using a 90-day reference period approach and following the guidelines published by WHO. The analysis failed to identify any major difference in the vaginal bleeding patterns induced by both contraceptive preparations. For both drugs, the first bleeding episode following the first injection occurs early. For 70% of users, this is followed by a regular vaginal bleeding pattern similar to an untreated pattern. Others experience irregular bleeding and a few have either infrequent or frequent bleeding. The extremes of amenorrhea and prolonged bleeding are rare. There are no major trends in vaginal bleeding patterns with prolonged use of either preparation. Women with the worst vaginal bleeding patterns discontinue early in the clinical trial and the last three months of experience have the most influence in their decision to stop using the contraceptive method. The analysis suggests how the life-table analysis of discontinuation reasons underestimates the true incidence of vaginal bleeding irregularities in a clinical trial.
- Published
- 1989
10. P67 Menopause in Systemic Lupus Erythematosus SLE Age at Presentation and Clinical Characteristics
- Author
-
Cravioto, M. C., Romero-Díaz, J., Mendoza-Fuentes, A., Mestanza-Peralta, M., and Sánchez-Guerrero, J.
- Published
- 1998
11. P66 Pharmacokinetic and Pharmacodynamic Assessment of the 25mg Estradiol Releasing Subcutaneous Implant in Postmenopausal Women
- Author
-
Cravioto, M. C., Delgado-Baldizón, N., Rico-Escobar, A., Díaz-Sánchez, V., and Larrea, F.
- Published
- 1998
12. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus.
- Author
-
Sánchez-Guerrero J, Villegas A, Mendoza-Fuentes A, Romero-Díaz J, Moreno-Coutiño G, and Cravioto MC
- Subjects
- Anti-Inflammatory Agents metabolism, Antirheumatic Agents metabolism, Chloroquine metabolism, Cohort Studies, Disease Progression, Emergency Service, Hospital, Female, Hospitalization, Humans, Immunosuppressive Agents metabolism, Medical Records, Middle Aged, Patient Acceptance of Health Care, Prednisone metabolism, Retrospective Studies, Lupus Erythematosus, Systemic metabolism, Postmenopause metabolism, Premenopause metabolism
- Abstract
Purpose: Cyclophosphamide-induced ovarian failure has been reported to be protective against flares of systemic lupus erythematosus (SLE). We studied whether patients with SLE experience a decrease in disease activity after natural menopause., Subjects and Methods: We studied 30 SLE patients with natural menopause who had been observed at least 2 years before and after menopause and who did not receive hormone replacement therapy or danazol. Menopause was defined as the date of the last self-reported menstrual period. Disease activity was assessed retrospectively by medical chart review using standard measures (the SLE disease activity index) during the immediate premenopausal and postmenopausal periods, and 2 (n = 30 patients), 3 (n = 19), and 4 (n = 13) years before and after menopause. We also compared the use of health services and medications., Results: Patients were studied for a mean (+/- SD) of 6.4 +/- 1.7 years (premenopausal, 3.3 +/- 0.9 years; postmenopausal, 3.2 +/- 0.9 years). During the premenopausal periods, the mean disease activity score was 2.3 +/- 2.3 (range, 0 to 9 on a 0 to 105 scale), compared with 2.3 +/- 2.9 (range, 0 to 12; P = 0.37) after menopause. The maximum disease activity score was somewhat greater in the premenopausal period (7.9 +/- 6.0 [range, 0 to 22] vs. 5.8 +/- 5.1 [range, 0 to 22]; P = 0.04). The incidence rates of flares (0.56 per year vs. 0.43 per year, P = 0.20) and severe flares (0.17 per year vs. 0.12 per year, P = 0.33) were similar in the premenopausal and postmenopausal periods. Differences in disease activity scores (mean and maximum) and the number of visits to a rheumatologist's office were only significant when the fourth year before menopause was compared with the fourth year after menopause., Conclusions: Disease activity is mild during the premenopausal and postmenopausal periods in women with SLE. A modest decrease, especially in the maximum disease activity, is seen after natural menopause.
- Published
- 2001
- Full Text
- View/download PDF
13. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
- Author
-
Hernández I, Parra A, Méndez I, Cabrera V, Cravioto MC, Mercado M, Díaz-Sánchez V, and Larrea F
- Subjects
- Adolescent, Adult, Area Under Curve, Blood Glucose analysis, Dehydroepiandrosterone Sulfate blood, Estradiol metabolism, Fasting blood, Female, Follicle Stimulating Hormone metabolism, Humans, Insulin blood, Luteinizing Hormone metabolism, Lymphoma pathology, Obesity complications, Obesity physiopathology, Polycystic Ovary Syndrome complications, Prolactin blood, Prolactin pharmacology, Secretory Rate drug effects, Testosterone metabolism, Thyrotropin metabolism, Tumor Cells, Cultured drug effects, Dopamine physiology, Dopamine Antagonists, Hypothalamo-Hypophyseal System physiopathology, Hypothalamus physiopathology, Metoclopramide, Polycystic Ovary Syndrome physiopathology, Prolactin metabolism
- Abstract
Background: The present study was carried out to investigate the functional significance of the reduced dopaminergic tone in subjects affected with polycystic ovary syndrome (PCOS)., Methods: Our group evaluated the response of pituitary PRL, LH, FSH, and TSH to the administration of a single 10-mg oral dose of the dopamine (DA) receptor antagonist metoclopramide in lean (n = 7) and obese (n = 8) PCOS women and in 11 regularly cycling age- and weight-matched controls (six lean and five obese). In addition, circulating PRL bioactivity was evaluated by its mitogenic activity on a lymphoma cell bioassay., Results: Oral administration of metoclopramide resulted in a significant increase in serum PRL in all subjects; however, the highest increments, regardless of body mass index (BMI), were observed in control women (p <0.005). Measurements of PRL mitogenic activity on the Nb2 lymphoma cell bioassay revealed a significant increase in the bioactive/immunoreactive (B/I) ratio of PRL under basal and stimulated conditions in obese PCOS subjects (p <0.05). Mean fasting glucose/insulin and glucose/insulin-AUC ratios were significantly lower (p <0.001) in obese PCOS when compared with all other groups., Conclusions: These data support the existence of low DA hypothalamic tone in PCOS women that is likely involved in the inappropriate LH and PRL secretion frequently seen in this syndrome. In addition, our results suggest changes in PRL bioactivity in obese PCOS that may play a role in the development of hyperinsulinemia; however, whether PRL has a functional significance in the development of the metabolic disturbances frequently seen in PCOS remains to be elucidated.
- Published
- 2000
- Full Text
- View/download PDF
14. Prolactin size variants during pregnancy in women with ovulatory hyperprolactinemia: characterization by isoelectric focusing and lectin affinity chromatography.
- Author
-
Larrea F, Méndez I, Escorza A, Veayra F, Cariño C, and Cravioto MC
- Subjects
- Adult, Chromatography, Affinity, Female, Glycosylation, Humans, Isoelectric Focusing, Molecular Structure, Molecular Weight, Ovulation, Pregnancy metabolism, Prolactin metabolism, Hyperprolactinemia metabolism, Pregnancy Complications metabolism, Prolactin chemistry
- Abstract
Previous studies from this laboratory have demonstrated the occurrence of important changes in PRL size heterogeneity in women with ovulatory hyperprolactinemia during gestation. A similar observation has been made, in normal women, for glycosylated PRL, which shows a progressive decrease as pregnancy progresses. In this study we decided to investigate the contribution of G-PRL on PRL heterogeneity throughout gestation in women with ovulatory hyperprolactinemia. Serum samples obtained throughout gestation were analysed by SDS-PAGE followed by immunoblotting and by isoelectric focusing of gels as well. The results indicated that, independent of the stage of pregnancy, the relative amounts of G-PRL as compared with the nonglycosylated form of the hormone remained quite constant. In addition, isoelectric focusing analyses of serum samples consistently resulted in an identical isoelectric point of PRL throughout all of the gestational period. These results suggested that changes in the relative proportions of PRL size species during pregnancy were not correlated with the degree of PRL glycosylation. Moreover, these observations further extended and supported the concept that the occurrence of PRL size heterogeneity depends mainly on thiol-disulfide interchange mechanisms, among PRL molecules, at the pituitary level.
- Published
- 1992
- Full Text
- View/download PDF
15. [Prolactin variants in serum and amniotic fluid of women with ovulatory hyperprolactinemia].
- Author
-
Larrea F, Escorza A, Méndez I, Ruiz JE, Valero A, and Cravioto MC
- Subjects
- Adult, Chorion metabolism, Estradiol blood, Female, Humans, Hyperprolactinemia physiopathology, Molecular Weight, Obstetric Labor Complications blood, Pituitary Neoplasms complications, Pituitary Neoplasms metabolism, Postpartum Period blood, Pregnancy, Pregnancy Complications physiopathology, Pregnancy Complications, Neoplastic metabolism, Progesterone blood, Prolactin analysis, Prolactin metabolism, Prolactinoma complications, Prolactinoma metabolism, Amniotic Fluid chemistry, Hyperprolactinemia metabolism, Ovary metabolism, Pregnancy Complications metabolism, Prolactin chemistry
- Abstract
There is enough evidence that prolactin (PRL), like many other pituitary hormones, is composed by multiple forms that differ from each other by size charge. Although they can be seen in the pituitary glands of a variety of species, their biological significance, identity and chemical nature still remain poorly understood. Recently, a new syndrome characterized by normal ovarian function in the presence of sustained hyperprolactinemia has been reported by our group. In these women, highly abnormal percentages of serum big big PRL have been consistently demonstrated. This observation suggests that big big PRL is immunologically similar, but biologically less active than monomeric or little PRL. In this study we have determined then molecular size heterogeneity of immunoreactive PRL in serum and amniotic fluid from two ovulatory hyperprolactinemic subjects (subjects A and B) who had, under non-pregnant conditions, large amounts of serum big big PRL, throughout different stages of parturition. Control subjects consisted of two women at the end of pregnancy in whom PRL species demonstrated a normal size distribution (subjects C and D). Mean basal levels of PRL were the highest in subjects A and B and remained constant during labor. In the control subjects a remarkable decline in PRL levels was observed during the periparturitional period. This pattern of PRL release was not correlated with changes in steroid hormone concentrations. The relative proportions of PRL size variants throughout delivery showed no apparent changes in all four subjects.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1991
16. Familial occurrence of big-big prolactin as the predominant immunoreactive human prolactin species in blood.
- Author
-
Larrea F, Escorza A, Granados J, Valencia X, Valero A, Cravioto MC, and Pérez-Palacios G
- Subjects
- Adult, Female, Genotype, HLA Antigens analysis, Haploidy, Humans, Hyperprolactinemia blood, Hyperprolactinemia genetics, Major Histocompatibility Complex, Male, Metoclopramide, Molecular Weight, Prolactin blood, Prolactin genetics
- Abstract
The occurrence of big-big prolactin (PRL) as the major form of circulating immunoactive PRL has been described in ovulatory hyperprolactinemia. In this study, we have analyzed the heterogeneity of circulating human PRL in 17 members of three families in which one member, bearing galactorrhea-hyperprolactinemic syndrome, was known to have serum big-big PRL as the predominant circulating species. Gel filtration patterns of serum samples of all subjects revealed the presence of significant proportions of big-big PRL in more than one member of the same family, thus suggesting the familial occurrence of big-big as the predominant immunoreactive PRL species in blood.
- Published
- 1987
17. Ovarian function following a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses.
- Author
-
Bassol S, Garza-Flores J, Cravioto MC, Diaz-Sanchez V, Fotherby K, Lichtenberg R, and Perez-Palacios G
- Subjects
- Adolescent, Adult, Dose-Response Relationship, Drug, Estradiol blood, Female, Humans, Kinetics, Medroxyprogesterone blood, Medroxyprogesterone pharmacology, Medroxyprogesterone Acetate, Mexico ethnology, Ovulation drug effects, Progesterone blood, Thailand ethnology, Medroxyprogesterone analogs & derivatives, Ovary drug effects
- Abstract
The effects of a single administration of depo-medroxyprogesterone acetate (DMPA) at different doses upon ovarian function was studied in a group of healthy ovulating Mexican women. Single doses of DMPA of 25, 50, 100, and 150 mg were intramuscularly administered. Ovarian function was assessed by the measurement of the serum levels of 17 beta-estradiol and progesterone in blood samples drawn twice weekly for 6 months after DMPA administration. The results disclosed that ovulation was inhibited in all cases for at least 3 months following DMPA administration even at the lowest dose, whereas the return of luteal function exhibited a significant positive correlation with the dose of DMPA administered. As expected, follicular activity preceded that of luteal function in all subjects. A correspondence between serum medroxyprogesterone concentrations and ovarian function was found. The overall data indicated that the currently used contraceptive formulation (150 mg) is well above the effective pharmacologic range, and suggested that the dose can be substantially reduced without losing its anovulatory potency.
- Published
- 1984
18. Estrogen-progestogen once-a-month injectable contraceptives and serum prolactin.
- Author
-
Garza-Flores J, Alba VM, Cravioto MC, Hernandez L, Perez-Palacios G, Alvarado G, Rivera R, Recio R, and Bassol S
- Subjects
- Adult, Algestone Acetophenide administration & dosage, Contraceptives, Oral, Synthetic administration & dosage, Delayed-Action Preparations, Estradiol administration & dosage, Estradiol analogs & derivatives, Estradiol blood, Female, Humans, Injections, Intrauterine Devices, Copper, Medroxyprogesterone administration & dosage, Medroxyprogesterone analogs & derivatives, Medroxyprogesterone Acetate, Norethindrone administration & dosage, Norethindrone analogs & derivatives, Random Allocation, Contraceptives, Oral, Combined administration & dosage, Prolactin blood
- Abstract
To assess the effect of hormonal monthly injectable contraceptives upon the serum values of immunoreactive prolactin (Prl), three groups of women of reproductive age exposed to different estrogen-progestogen injectable formulation for a minimum of one year were studied. The first group (n = 10) received dihydroxyprogesterone acetophenide 150 mg and estradiol enanthate 10 mg (DHPA/E2-EN), Group 2 (n = 21) received medroxyprogesterone acetate 25 mg and estradiol cypionate 5 mg (MPA/E2-C) and Group 3 (n = 19) was exposed to norethisterone enanthate 50 mg and estradiol valerate 5 mg (NET-EN/E2-V). A group of IUD users (n = 16) served as the control group. Serum Prl and 17 beta-estradiol (E2) concentration were determined in blood samples (0 and 15 min.) on days 0 (day of last injection), 10, 20 and 30 after last contraceptive injection. The results demonstrated a slight though not significant increase (p greater than 0.05) in serum Prl in the three experimental groups as compared with the IUD control group. This increase in Prl levels observed on day 10 post-last injection never exceeded the upper limits of the normal range (20 ng/ml). Overall, the data demonstrated that the chronic administration of these estrogen/progestogen once-a-month injectable contraceptives does not affect the Prl baseline secretion in women.
- Published
- 1989
- Full Text
- View/download PDF
19. [Effectiveness of injectable contraceptives in Mexican women].
- Author
-
Garza-Flores J, Rodríguez V, Cravioto MC, del Real Mora O, Anderson J, Landeros J, Díaz Sánchez V, Lichtenberg R, and Pérez-Palacios G
- Subjects
- Adolescent, Adult, Delayed-Action Preparations, Drug Evaluation, Female, Humans, Medroxyprogesterone administration & dosage, Medroxyprogesterone Acetate, Mexico, Norethindrone administration & dosage, Patient Acceptance of Health Care, Patient Dropouts, Pregnancy, Contraceptive Agents, Female administration & dosage, Medroxyprogesterone analogs & derivatives, Norethindrone analogs & derivatives
- Published
- 1985
20. Heterogeneity of serum prolactin throughout the menstrual cycle and pregnancy in hyperprolactinemic women with normal ovarian function.
- Author
-
Larrea F, Escorza A, Valero A, Hernandez L, Cravioto MC, and Diaz-Sanchez V
- Subjects
- Adult, Chromatography, Gel, Estradiol blood, Female, Fetal Blood analysis, Humans, Hyperprolactinemia genetics, Infant, Newborn, Molecular Weight, Progesterone blood, Prolactin genetics, Hyperprolactinemia blood, Menstrual Cycle, Ovary physiology, Pregnancy blood, Prolactin blood
- Abstract
We have demonstrated the selective secretion of high mol wt PRL series (big big PRL) in women with hyperprolactinemia and normal ovarian function. This observation suggests that big big PRL is immunologically similar, but biologically less active, than monomeric or little PRL. In this study we determined the molecular size heterogeneity of immunoreactive PRL in the serum from two ovulatory hyperprolactinemic women (subjects A and B) who had large amounts of serum big big PRL during a menstrual cycle and/or gestation. Serum samples obtained throughout the menstrual cycle (days 6, 10, 14, 17, 23, and 28, taking as day 1 the first day of bleeding) and pregnancy (weeks 7, 9, 11, 15, 20, 25, 30, 34, and 38) were fractionated by gel filtration chromatography. PRL was identified in column eluates by specific RIA. Two additional pregnant women, one with a bromocriptine-treated PRL-secreting adenoma (subject C), and a normal woman (subject D) were studied. Big big PRL was the predominant species throughout the different phases of the menstrual cycle in subject B, comprising 70-80% of the total immunoreactive PRL. Most of the remainder was big PRL, and little PRL was present in only small amounts (6-12%) during the luteal phase. During their pregnancies, the serum PRL in subjects A and B initially was mostly big big PRL, but later in gestation the PRL composition shifted from the high mol wt variants to little PRL. The infant's cord (subject A) and peripheral (subject B) serum at birth contained appreciable quantities of big big and big PRL, respectively. These results indicate that structural changes in PRL occur during pregnancy and the menstrual cycle which are probably influenced by the hormonal environment. In addition, the occurrence of larger mol wt PRL species in the serum of the infant of a hyperprolactinemic mother suggests that the presence of high proportions of big big PRL in the serum is genetically determined.
- Published
- 1989
- Full Text
- View/download PDF
21. Return to ovulation following the use of long-acting injectable contraceptives: a comparative study.
- Author
-
Garza-Flores J, Cardenas S, Rodríguez V, Cravioto MC, Diaz-Sanchez V, and Perez-Palacios G
- Subjects
- Adult, Female, Humans, Medroxyprogesterone adverse effects, Medroxyprogesterone Acetate, Menstrual Cycle drug effects, Norethindrone adverse effects, Progesterone blood, Time Factors, Medroxyprogesterone analogs & derivatives, Norethindrone analogs & derivatives, Ovulation drug effects
- Abstract
A comparative study was undertaken in twenty-four Mexican women who discontinued the use of depo-medroxyprogesterone acetate (DMPA) or norethisterone enanthate (NET-EN) to assess the time required for the return to menses and ovulation. All subjects were exposed to long-acting injectable contraceptives for at least one year, and were followed prospectively. Serum progesterone levels were determined weekly in all subjects beginning 3 months after the last progestogen injection. Mean time to return to ovulation occurred significantly earlier (p less than 0.001) after NET-EN (2.6 months) as compared with DMPA (5.5 months). No correlation between the return to ovarian function and the duration of steroid exposure was found. The overall data was interpreted as demonstrating a clear-cut difference between the two long-acting progestogens in terms of ovulation suppression.
- Published
- 1985
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.